CXCL12 rs1801157 polymorphism in patients with breast cancer, hodgkin's lymphoma, and non‐hodgkin's lymphoma

Abstract

Chemokines and their receptors regulate the trafficking of immune cells during their development, inflammation, and tissue repair. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/ stromal cell-derived factor-1 (SDF1)-3'A) in CXCL12/SDF1 gene was assessed in breast cancer, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL), since the chemokine CXCL12, previously known as SDF1, and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis, and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using a restriction enzyme HpaII cleavage. No significant difference was observed in genotype distribution between breast cancer patients (GG: 57.3%; GA: 39.8%; AA: 2.9%) and healthy female controls (GG: 62.9%; GA: 33%; AA: 4.1%) nor between HL patients (GG: 61.1%; GA:27.8%; AA: 11.1%) and healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%), whereas a significant difference was observed in genotype distribution between NHL patients (GG: 51.4%; GA: 47.1%; AA: 1.5%) and healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%). Further studies will be necessary to elucidate the cancer chemokine network. However, this study suggests that CXCL12 rs1801157 polymorphism may have important implications in the pathogenesis of NHL.

Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin’s lymphoma

“…Inflammation sustains the proliferation of cancer cells by stromal cells activation and chemokines secretion. Some chemokines, such as CXCL12 and CXCL13, have proven roles in the pathogenesis of lymphoma [47,48].…”

Distribution of SDF1-3’A, GNB3 C825T and MMP-9 C-1562T Polymorphisms in HSC CD34+ from Peripheral Blood of Patients with Hematological Malignancies

“…In fact, Association of these polymorphisms to cancer has been previously reported by many investigators [De Oliveira KB et al, 2009;Rabkin CS et al, 1999].…”

“…Whereas, they didn't find any significant differences in genotypes distributions with breast cancer and Hodgkin's lymphoma [De Oliveira KB et al, 2009].…”

Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues

“…Several studies have examined the association between disease susceptibility and the CXCL12-G801A polymorphism (27)(28)(29)(30)(31)(32)(33). These studies indicated that the CXCL12-G801A polymorphism was associated with an increased risk of HIV infection, lung cancer, breast cancer, acute leukemia, prostate cancer, non-Hodgkin's lymphoma and oral squamous cell carcinoma (27)(28)(29)(30)(31)(32)(33)(34). However, only a small number of studies focused on the presence of the CXCL12-G801A polymorphism in CRC patients to clarify whether the CXCL12-G801A polymorphism is associated with disease susceptibility and clinical characteristics in CRC (31,35).…”